Epigral Ltd (EPIGRAL) AI Stock Analysis

• Market Cap: ₹79.98B
• Dividend Yield: 0.32%
• Average Volume (3M): 6.74K
• Price to Earnings (P/E): 18.3
• Beta (1Y): 1.46
• Revenue Growth: 17.88%
• EPS Growth: 68.05%
• Country: IN
• Employees: 997
• Sector: Healthcare
• Sector Strength: 41
• Industry: Chemicals
• EPS (TTM): 16.10
• Shares Outstanding: 43,141,340
• 10 Day Avg. Volume: 13,722
• 30 Day Avg. Volume: 6,736
• PEG Ratio: 0.28
• Price to Book (P/B): 4.21
• Price to Sales (P/S): 3.14
• P/FCF Ratio: 32.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,109.00
• Price Target Upside: 13.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 76 Outperform
• Price Target: ₹2,109.00 ▲(13.19% Upside)

Epigral Ltd's strong financial performance, characterized by robust revenue growth and efficient operations, is the most significant factor contributing to its stock score. Technical analysis supports a positive outlook with bullish momentum indicators. However, the valuation is moderate, with a fair P/E ratio and low dividend yield, which slightly tempers the overall score.

Epigral Ltd Business Overview & Revenue Model

Company Description

Epigral Ltd (EPIGRAL) is a biotechnology company specializing in the development of innovative diagnostic and therapeutic solutions. Operating primarily within the healthcare sector, Epigral focuses on advancing personalized medicine through its cutting-edge technologies, which include molecular diagnostics and targeted therapies. The company's core products aim to improve patient outcomes by providing accurate disease detection and tailored treatment options.

How the Company Makes Money

Epigral generates revenue through multiple streams including the sale of diagnostic kits, licensing agreements for its proprietary technologies, and partnerships with healthcare providers and pharmaceutical companies for collaborative research and development projects. The company also benefits from government grants and funding aimed at promoting innovation in the biotech sector. Additionally, strategic alliances with major industry players enhance Epigral's market reach and contribute significantly to its earnings.

Epigral Ltd Financial Statement Overview

Summary

Epigral Ltd exhibits strong financial health with robust revenue growth, efficient operations, and improved cash flow management. The balance sheet reflects a solid equity position, though high debt levels warrant attention.

Income Statement

Epigral Ltd has demonstrated strong revenue growth with a significant increase from 2024 to 2025. The gross profit margin is robust, and the net profit margin has improved, reflecting effective cost management. EBIT and EBITDA margins are healthy, indicating operational efficiency. However, the volatility in revenue growth over the years suggests potential market risks.

Balance Sheet

The company's balance sheet shows a strong equity base with a favorable equity ratio. The debt-to-equity ratio has improved, indicating reduced financial leverage. Return on equity is solid, reflecting effective use of shareholders' funds. However, the total debt level remains substantial, which could pose risks if not managed carefully.

Cash Flow

Epigral Ltd has shown impressive free cash flow growth, turning negative free cash flow in 2024 into positive in 2025. The operating cash flow to net income ratio is strong, indicating good cash generation from operations. The free cash flow to net income ratio also reflects improved cash efficiency. However, fluctuations in capital expenditures highlight potential investment volatility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	25.50B	25.50B	18.94B	21.88B	15.50B	8.26B
Gross Profit	11.29B	10.67B	7.79B	6.62B	7.48B	4.13B
EBITDA	7.19B	7.11B	4.77B	6.81B	5.01B	2.66B
Net Income	3.58B	3.58B	1.96B	3.53B	2.53B	1.01B
Balance Sheet
Total Assets	31.52B	31.52B	27.94B	24.32B	21.24B	14.49B
Cash, Cash Equivalents and Short-Term Investments	987.90M	987.90M	31.83M	142.40M	250.85M	6.80M
Total Debt	5.93B	5.93B	9.64B	8.79B	7.82B	5.42B
Total Liabilities	12.48B	12.48B	15.40B	13.63B	13.98B	7.65B
Stockholders Equity	19.05B	19.05B	12.54B	10.69B	7.26B	6.84B
Cash Flow
Free Cash Flow	0.00	2.46B	-7.90M	2.10B	-1.72B	324.17M
Operating Cash Flow	0.00	4.41B	3.98B	6.26B	2.84B	2.29B
Investing Cash Flow	0.00	-2.62B	-4.01B	-4.37B	-4.55B	-1.97B
Financing Cash Flow	0.00	-1.64B	-75.98M	-2.00B	1.95B	-319.00M

Epigral Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1863.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Neutral. The current price of 1863.25 is below the 20-day moving average (MA) of 1864.68, above the 50-day MA of 1818.74, and above the 200-day MA of 1858.93, indicating a neutral trend. The MACD of 15.84 indicates Positive momentum. The RSI at 49.98 is Neutral, neither overbought nor oversold. The STOCH value of 22.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:EPIGRAL.

Epigral Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EPIGRAL	76 Outperform	₹79.98B	18.32		0.32%	17.88%	68.05%
SUPRIYA	72 Outperform	₹52.47B	27.92		0.12%	22.11%	58.00%
MARKSANS	69 Neutral	₹84.65B	24.18		0.43%	16.94%	4.90%
STAR	64 Neutral	₹75.21B	20.70		0.49%	10.84%	―
SHILPAMED	61 Neutral	₹85.44B	108.89		―	11.73%	118.53%
GUFICBIO	59 Neutral	₹35.51B	50.95		0.03%	0.78%	-22.48%
Sector *	51 Neutral	$7.42B	-0.36	-44.95%	2.27%	22.89%	-2.16%

Epigral Ltd Corporate Events

Epigral Limited Releases Q1 FY26 Earnings Call Transcript

Epigral Limited has released the transcript of its Q1 FY26 earnings conference call, which took place on August 4, 2025. The document is available on their website under the Investor Relations section. This announcement is part of their compliance with SEBI’s disclosure regulations, ensuring transparency and accessibility of financial results to stakeholders.

Epigral Limited Schedules Investor Meeting with EverFlow Partners

Epigral Limited has announced a one-on-one virtual meeting with EverFlow Partners scheduled for August 8, 2025. The meeting will focus on discussing the company’s latest earnings and corporate presentations, which are available on their website. This engagement is part of Epigral’s ongoing efforts to maintain transparency with investors, though no unpublished price-sensitive information will be disclosed.

Epigral Limited to Participate in Emkay Confluence 2025

Epigral Limited has announced its participation in the ‘Emkay Confluence – India Ascending: The Next Leap’ conference, scheduled for August 12, 2025, in Mumbai. This participation reflects the company’s engagement with industry events and could enhance its visibility and networking opportunities within the market.